Variation in Endpoints for FDA Approved Migraine Therapies

<div> <p>Dr. Leigh Sharpless discusses her paper, "Variation in Endpoints in FDA Medication Approvals: A Review of Acute and Preventive Migraine Medications".</p> <p>Show References: <a href= "https://n.neurology.org/content/101/10/e989">https://n.neurology.org/content/101/10/e989</a></p> <p>https://directory.libsyn.com/episode/index/id/27962343</p> </div>